<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412853</url>
  </required_header>
  <id_info>
    <org_study_id>0203-1crgi 07/005-046</org_study_id>
    <nct_id>NCT01412853</nct_id>
  </id_info>
  <brief_title>Spectro-IRM and Evaluation Response to Prostatic Radiotherapy</brief_title>
  <acronym>ERIS</acronym>
  <official_title>Evaluation of the Response to Irradiation With MR-Spectroscopy for Localised Prostate Cancer Patients (The ERIS Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <brief_summary>
    <textblock>
      Context:&#xD;
&#xD;
      Prostate cancer is the most common non-cutaneous cancer and the second most common cause of&#xD;
      cancer-related deaths in European and North-American men.&#xD;
&#xD;
      After external radiotherapy or brachytherapy, the Prostate Specific Antigen (PSA) value is&#xD;
      often fluctuating and PSA nadir may only be reached after 2 years or more and may remain&#xD;
      detectable several years after the completion of radiation. Moreover, PSA bounces and blips&#xD;
      render patients and physicians very anxious about any possibility of a relapse. In this&#xD;
      context, biomarkers that could predict the response to radiation earlier than PSA for&#xD;
      patients with prostate cancer appear long overdue.&#xD;
&#xD;
      Magnetic Resonance Spectroscopy at 3 Tesla without endorectal coil is a non invasive&#xD;
      procedure which allows quantification of metabolites such as Choline, Creatine, Polyamines&#xD;
      and Citrate within the prostate gland.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The investigators are conducting a French prospective study on the Evaluation of the Response&#xD;
      to Irradiation with MR Spectroscopy (ERIS). Their purpose is to monitor the early response of&#xD;
      radiation with 3D MR Spectroscopy during the first year after completion of radiation and its&#xD;
      impact on biochemical control. Therefore, the ERIS trial aims to investigate whether or not&#xD;
      there could be a correlation between the time course of PSA and that of Choline and Citrate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2008</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA value compare to Choline and Citrate levels as measured with MR-spectroscopic imaging as predictive factor of the response to treatment</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Data will be collected at the end of the radiotherapy and every 3 months up to 1 year for each patient. Data analysis will be performed at the end of data completion in december 2011.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>MR-spectroscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MR-Spectroscopy</intervention_name>
    <description>response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy</description>
    <arm_group_label>MR-spectroscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a biopsy-proven prostatic adenocarcinoma&#xD;
&#xD;
          2. Gleason score between 4 and 10&#xD;
&#xD;
          3. Maximal baseline PSA &lt; 50 ng/ml&#xD;
&#xD;
          4. Age over or = to 18 yr&#xD;
&#xD;
          5. Exclusive radiotherapy and/or brachytherapy with or without androgen deprivation&#xD;
             therapy&#xD;
&#xD;
          6. Written informed consent from the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. lymph-node metastases&#xD;
&#xD;
          2. Bone metastases&#xD;
&#xD;
          3. Maximal baseline PSA ≥ 50 ng/ml&#xD;
&#xD;
          4. Prior radical prostatectomy&#xD;
&#xD;
          5. Contra-indications for MRI (Pace-maker, hip prothesis…)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

